<DOC>
	<DOCNO>NCT00672932</DOCNO>
	<brief_summary>This pilot study focus persistence central nervous system ( CNS ) immune activation observe presence 'effective ' combination antiretroviral therapy ( cART ) . Attention issue base fear chronic CNS immunoactivation cause indolent brain injury eventually compromise brain function patient survive year treatment . A leading hypothesis explain continued immunoactivation viral replication continue within brain level low detection cerebrospinal fluid ( CSF ) , yet sufficient stimulate local immunoactivation . Based hypothesis , propose use augment treatment raltegravir test whether additional suppression hypothesize CNS HIV-1 replication reduce continue CNS immunoactivation .</brief_summary>
	<brief_title>Raltegravir Augmentation Persistent Central Nervous System ( CNS ) Immunoactivation Treated HIV-1 Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Capacity provide informed consent . Documented HIV1 infection . History continuous cART treatment ( least three drug ) least 2 year . Documentation 'undetectable ' plasma HIV1 RNA least 1 year . HIV1 RNA &lt; 50 copies/mL plasma CSF screen visit . Contraindication LP ( suspicion CNS mass lesion , bleed diathesis , etc. ) . Prior experience raltegravir contraindication raltegravir treatment , include medication interaction might compromise ongoing antiretroviral therapy treatment condition . Active opportunistic infection neurological disease . Other condition treatment likely interfere treatment evaluation . Hemoglobin &lt; 10 Gm/dL . Pregnant anticipate pregnancy study . Active substance abuse . Subjects take rifampin , phenytoin , Phenobarbital drug accelerate raltegravir metabolism might decrease tissue concentration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>raltegravir</keyword>
	<keyword>central nervous system ( CNS )</keyword>
	<keyword>HIV-1</keyword>
	<keyword>AIDS</keyword>
	<keyword>cerebrospinal fluid ( CSF )</keyword>
	<keyword>immunoactivation</keyword>
	<keyword>antiretroviral therapy</keyword>
	<keyword>suppression</keyword>
</DOC>